All posts by: Michael Zand

About Michael Zand

Role of CAR T-Cell Therapy in Relapsed/Refractory ALL – OncLive

Continue reading

2018-04-04 NEWS

OncLive

Role of CAR T-Cell Therapy in Relapsed/Refractory ALL
OncLive
Aaron C. Logan, MD, PhD: It’s definitely exciting, but I think this particular generation of CAR T cells does carry a lot of toxicity, and it requires extreme expertise to administer this therapy to patients. I don’t think that 10 years from now, this
CAR T-Cell Therapy in ALL: Formidible Challenges Remain …Cancer Network
Global Cell Therapy Processing Market to Reach $5.0 Billion By 2022GlobeNewswire (press release)

all 7 news articles »

Continue reading

2018-04-04 NEWS

YouTube

Role of CAR T-Cell Therapy in Relapsed/Refractory ALL
OncLive
Aaron C. Logan, MD, PhD: It’s definitely exciting, but I think this particular generation of CAR T cells does carry a lot of toxicity, and it requires extreme expertise to administer this therapy to patients. I don’t think that 10 years from now, this
CAR T-Cell Therapy in ALL: Formidible Challenges RemainCancer Network

all 7 news articles »

Continue reading

2018-04-04 NEWS

YouTube

Role of CAR T-Cell Therapy in Relapsed/Refractory ALL
OncLive
Aaron C. Logan, MD, PhD: It’s definitely exciting, but I think this particular generation of CAR T cells does carry a lot of toxicity, and it requires extreme expertise to administer this therapy to patients. I don’t think that 10 years from now, this
CAR T-Cell Therapy in ALL: Formidible Challenges RemainCancer Network

all 7 news articles »